ArticleClinical hypertension2024
Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations.
Article in Clinical hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Physical activity for prevention of cardiovascular disease: consensus statement of Korean Society of Cardio-cerebrovascular Disease Prevention.The Korean journal of internal medicine · 2025Guideline
- Dietary management and aerobic exercise counselling on blood pressure control in subjects with prehypertension and drug-naïve stage 1 hypertension: a randomized clinical trial.Scientific reports · 2025Trial
- Efficacy of Olmesartan/Amlodipine Single-Pill Combination on 24-h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non-Responders to Valsartan or Candesartan Monotherapy.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Sleep quality and hypertension: a counterfactual mediation analysis of the role of depressive symptoms.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Comparative bleeding risk between angiotensin II receptor blockers with high versus low P-glycoprotein inhibitory activity in patients with atrial fibrillation receiving direct oral anticoagulants.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Analysis of demographic factors and consumption habits on hypertension in the adult population in Indonesia: (Health Indonesian survey 2023).Journal of public health research · 2026Article
- Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies.Advances in therapy · 2026Article
- Article
- Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia.Journal of lipid and atherosclerosis · 2026Article
- Doxazosin GITS (gastrointestinal therapeutic system) is an actor to consider in the control of hypertension. A narrative review.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- MsrB2 deficiency amplifies ECM-driven cardiac fibrosis under hypertensive stress.Frontiers in physiology · 2026Article
- To be (IIb), or not to be (IIb) - That is the current status of cuffless blood pressure monitoring device.Clinical hypertension · 2026Review
- Korea Hypertension Fact Sheet 2025: national trends in hypertension with a special analysis of hypertensive disorders of pregnancy.Clinical hypertension · 2026Article
- National trends in the unmet healthcare needs among patients with hypertension or type 2 diabetes mellitus in Korea from 2009 to 2023.Scientific reports · 2025Article
- Impact of Hydrochlorothiazide on Nonmelanoma Skin Cancer: A Distributed Network Analysis of 11 Real-world Databases.Annals of dermatology · 2025Article
- Current status of the use of validated home blood pressure monitoring devices among Korean patients with hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022.Journal of obesity & metabolic syndrome · 2025Article
- [Geographic Disparities in Chronic Disease Indicators in the Chungcheong Region: Analysis Based on the 2024 Korea Community Health Survey].Jugan geon-gang gwa jilbyeong · 2025Article
- Lifestyle interventions for hypertension management in primary care: a narrative review.Ewha medical journal · 2025Article
- Association of Hypertension With Telomere Length, Considering Non-Genetic and Genetic Factors, in Middle-Aged Koreans.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, offers an overview of the prevalence and management of hypertension, along with recent trends.
methodsData for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021.
resultsAs of 2021, hypertension affected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 million individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medications rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihypertensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure < 130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years.
conclusionIn Korea, hypertension management is making strides, yet the total number of hypertensive individuals is rising. Effectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efficient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.